Key clinical point: Individuals with ankylosing spondylitis (AS) who took cyclooxygenase 2 (COX-2) inhibitors had a reduced risk of cardiovascular events, compared with AS patients who were not using COX-2 inhibitors.
Major finding: Individuals with AS taking COX-2 inhibitors had a risk ratio of 0.48 for cardiovascular events (95% CI, 0.33-0.70; P = .001).
Study details: Systematic review and meta-analysis of nine observational studies that variably examined the association between NSAID use and tumor necrosis factor inhibitor use and cardiovascular events among individuals with AS.
Disclosures: The authors reported no conflicts of interest and no outside sources of funding.
Karmacharya P. et al. SPARTAN 2019.
This Week's Must Reads
Must Reads in Acute Coronary Syndromes
hsCRP Levels & Adverse CE Events After ACS, JAMA Cardiol; ePub 2019 Mar 6; Mani, et al
Predischarge Cardiac Testing in a Chest Pain Unit, Am J Cardiol; ePub 2019 Mar 8; Howell, et al
Serum Uric Acid, Silent MI & Mortality, Am J Cardiol; ePub 2018 Dec 19; Ahmad, et al